A Payers’ Guide to New FDA Approvals is published annually by American Health & Drug Benefits to offer payers and other healthcare stakeholders a detailed analysis of new drugs approved by the US Food and Drug Administration (FDA) in the previous year, as well as an overview of the key drugs in the pipeline. This Guide includes in-depth updates on some of the new drugs that have either recently been launched or are soon to be launched, providing an important resource for medical and pharmacy directors for their benefit design decision-making. This edition represents the fourth year of publication of this Guide by American Health & Drug Benefits; it was first published in 2010. Each edition has expanded the scope of drug profiles coverage and the discussion of FDA approvals.
The 2013 edition includes in-depth updates on 17 of the drugs that had been approved by the FDA in 2012. This edition also includes a detailed introduction, “New FDA Drug Approvals in 2012: A 15-Year High”, focusing on some of the key trends that became apparent in the FDA approval process in 2012. In addition, the “Trends in the 2013 Pharmaceutical Pipeline” features key players in the current pharmaceutical pipeline, highlighting the major clinical categories in drug development in the 2013 pipeline, as well as some of the main trends in pharmaceutical research and development.
American Health & Drug Benefits will continue to expand the scope of this Guide in the coming years to offer healthcare stakeholders a tool for applying up-to-date information on new pharmaceuticals to their benefit design.
We hope you find this Guide useful, and we welcome your feedback. Send any comments to This email address is being protected from spambots. You need JavaScript enabled to view it..